IMMP
Price
$1.61
Change
-$0.06 (-3.59%)
Updated
Apr 3 closing price
Capitalization
238.01M
54 days until earnings call
NBY
Price
$0.56
Change
-$0.01 (-1.75%)
Updated
Apr 3 closing price
Capitalization
3.27M
Ad is loading...

IMMP vs NBY

Header iconIMMP vs NBY Comparison
Open Charts IMMP vs NBYBanner chart's image
Immutep
Price$1.61
Change-$0.06 (-3.59%)
Volume$174.48K
Capitalization238.01M
NovaBay Pharmaceuticals
Price$0.56
Change-$0.01 (-1.75%)
Volume$45.59K
Capitalization3.27M
IMMP vs NBY Comparison Chart
Loading...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMMP vs. NBY commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMMP is a Buy and NBY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IMMP: $1.61 vs. NBY: $0.56)
Brand notoriety: IMMP and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMMP: 233% vs. NBY: 64%
Market capitalization -- IMMP: $238.01M vs. NBY: $3.27M
IMMP [@Biotechnology] is valued at $238.01M. NBY’s [@Biotechnology] market capitalization is $3.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMMP’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 0 green FA rating(s).

  • IMMP’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 0 green, 5 red.
According to our system of comparison, NBY is a better buy in the long-term than IMMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMMP’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 3 bullish TA indicator(s).

  • IMMP’s TA Score: 4 bullish, 4 bearish.
  • NBY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, IMMP is a better buy in the short-term than NBY.

Price Growth

IMMP (@Biotechnology) experienced а -11.54% price change this week, while NBY (@Biotechnology) price change was -7.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

IMMP is expected to report earnings on May 28, 2025.

NBY is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMMP($238M) has a higher market cap than NBY($3.27M). NBY YTD gains are higher at: -6.439 vs. IMMP (-25.806). NBY has higher annual earnings (EBITDA): -6.52M vs. IMMP (-43.83M). IMMP has more cash in the bank: 159M vs. NBY (776K). NBY has less debt than IMMP: NBY (1.26M) vs IMMP (1.69M). NBY has higher revenues than IMMP: NBY (13.8M) vs IMMP (0).
IMMPNBYIMMP / NBY
Capitalization238M3.27M7,278%
EBITDA-43.83M-6.52M672%
Gain YTD-25.806-6.439401%
P/E RatioN/AN/A-
Revenue013.8M-
Total Cash159M776K20,490%
Total Debt1.69M1.26M134%
FUNDAMENTALS RATINGS
IMMP vs NBY: Fundamental Ratings
IMMP
NBY
OUTLOOK RATING
1..100
5355
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
8382
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (44) in the Biotechnology industry is somewhat better than the same rating for IMMP (84). This means that NBY’s stock grew somewhat faster than IMMP’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMMP (100). This means that NBY’s stock grew similarly to IMMP’s over the last 12 months.

IMMP's SMR Rating (96) in the Biotechnology industry is in the same range as NBY (100). This means that IMMP’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (82) in the Biotechnology industry is in the same range as IMMP (83). This means that NBY’s stock grew similarly to IMMP’s over the last 12 months.

NBY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMMP (100). This means that NBY’s stock grew similarly to IMMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMMPNBY
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
85%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRX0.310.01
+1.82%
TRX Gold Corp
VSEC116.76-7.55
-6.07%
VSE Corp
GMRE8.02-0.57
-6.64%
Global Medical REIT
KWE0.24-0.03
-9.77%
Kwesst Micro Systems Inc
ITT119.56-13.88
-10.40%
ITT

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been loosely correlated with PRTG. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NBY jumps, then PRTG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-1.70%
PRTG - NBY
38%
Loosely correlated
-13.61%
ALT - NBY
30%
Poorly correlated
-6.69%
ORMP - NBY
29%
Poorly correlated
-1.82%
DARE - NBY
25%
Poorly correlated
+0.69%
IMMP - NBY
25%
Poorly correlated
-3.59%
More